Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
Related Questions
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL.
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How do you approach c-KIT mutated, core binding factor (CBF) AML?
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
